Table 1.
Crude and age-adjusted incidence rates of lymphoid neoplasms diagnosed in Spain, 2002-2013.
| Subtype | ICD-O-3 codes | N. of cases | % | Median Age | CR95% CI | ASIRe95% CI | Sex ratio |
|---|---|---|---|---|---|---|---|
| Lymphoid neoplasm, total | 39,156 | 100.00 | 67 | 31.23 (30.92-31.54) | 34.23 (33.89-34.57) | 1.22 | |
| 1) Hodgkin lymphoma | 3,667 | 9.37 | 36 | 2.92 (2.83-3.02) | 2.84 (2.74-2.93) | 1.38 | |
| 1.1 Classical Hodgkin lymphoma | 9650-9655, 9661-9667 | 3,455 | 8.82 | 36 | 2.76 (2.66-2.85) | 2.67 (2.58-2.76) | 1.33 |
| 1.1.1 Lymphocyte-rich classical Hodgkin lymphoma | 9651 | 202 | 0.52 | 43 | 0.16 (0.14-0.18) | 0.16 (0.14-0.18) | 2.37 |
| 1.1.2 Nodular sclerosis classical Hodgkin lymphoma | 9663-9667 | 1,906 | 4.87 | 31 | 1.52 (1.45-1.59) | 1.43 (1.37-1.5) | 1.00 |
| 1.1.3 Mixed cellularity classical Hodgkin lymphoma | 9652 | 727 | 1.86 | 45 | 0.58 (0.54-0.62) | 0.58 (0.53-0.62) | 2.00 |
| 1.1.4 Lymphocyte-depleted classical Hodgkin lymphoma | 9653-9655 | 96 | 0.25 | 52 | 0.08 (0.06-0.09) | 0.08 (0.06-0.09) | 2.43 |
| 1.1.5 Classical Hodgkin lymphoma, NOS | 9650,9661-9662 | 524 | 1.34 | 45 | 0.42 (0.38-0.45) | 0.42 (0.38-0.46) | 1.61 |
| 1.2 Nodular lymphocyte predominant Hodgkin lymphoma | 9659 | 212 | 0.54 | 38 | 0.17 (0.15-0.19) | 0.17 (0.14-0.19) | 2.53 |
| Non-Hodgkin lymphoma | 35,489 | 90.64 | 69 | 28.30 (28.01-28.6) | 31.39 (31.06-31.72) | 1.21 | |
| 2) Precursor lymphoid neoplasms | 1,574 | 4.02 | 18 | 1.26 (1.19-1.32) | 1.31 (1.24-1.37) | 1.48 | |
| 2.1 B-lymphoblastic leukemia/lymphoma | 9728, 9811-9819, 9836 | 508 | 1.30 | 17 | 0.41 (0.37-0.44) | 0.42 (0.38-0.46) | 1.07 |
| 2.2 T-lymphoblastic leukemia/lymphoma | 9729, 9837 | 242 | 0.62 | 21 | 0.19 (0.17-0.22) | 0.20 (0.17-0.22) | 3.03 |
| 2.3 Lymphoblastic leukemia/lymphoma | 9727, 9835 | 824 | 2.10 | 18 | 0.66 (0.61-0.7) | 0.69 (0.64-0.74) | 1.50 |
| 3) Mature B-cell neoplasms | 29,429 | 75.16 | 69 | 23.47 (23.2-23.74) | 26.17 (25.87-26.47) | 1.19 | |
| 3.1 Chronic lymphocytic leukemia/small lymphocytic lymphoma | 9670, 9823 | 6,167 | 15.75 | 73 | 4.92 (4.8-5.04) | 5.61 (5.47-5.75) | 1.41 |
| 3.2 B-cell prolymphocytic leukemia | 9833 | 29 | 0.07 | 72 | 0.02 (0.01-0.03) | 0.03 (0.02-0.04) | 0.93 |
| 3.3 Mantle cell lymphoma | 9673 | 896 | 2.29 | 69 | 0.71 (0.67-0.76) | 0.81 (0.76-0.87) | 2.28 |
| 3.4 Lymphoplasmacytic lymphoma/Waldenström’s Macroglobulinemia | 9671, 9761 | 880 | 2.25 | 72 | 0.70 (0.66-0.75) | 0.80 (0.74-0.85) | 1.75 |
| 3.5 Diffuse large B-cell lymphoma | 9675, 9678-9680, 9684, 9688, 9712, 9735, 9737-9738 | 6,933 | 17.71 | 68 | 5.53 (5.4-5.66) | 6.04 (5.9-6.19) | 1.16 |
| 3.6 Burkitt lymphoma/leukemia | 9687, 9826 | 428 | 1.09 | 38 | 0.34 (0.31-0.37) | 0.35 (0.32-0.39) | 2.04 |
| 3.7 Marginal zone lymphoma | 9689, 9699, 9764 | 2,105 | 5.38 | 65 | 1.68 (1.61-1.75) | 1.84 (1.76-1.92) | 1.02 |
| 3.7.1 Splenic marginal zone lymphoma | 9689 | 403 | 1.03 | 68 | 0.32 (0.29-0.35) | 0.36 (0.33-0.4) | 0.91 |
| 3.7.2 Extranodal marginal zone lymphoma | 9699 (excluding C77.0-C77.9) | 1,421 | 3.63 | 62 | 1.13 (1.07-1.19) | 1.23 (1.16-1.29) | 1.06 |
| 3.7.3 Nodal marginal zone lymphoma | 9699 (C77.0-C77.9) | 280 | 0.72 | 66 | 0.22 (0.2-0.25) | 0.25 (0.22-0.28) | 0.96 |
| 3.8 Follicular lymphoma | 9597, 9690, 9691, 9695, 9698 | 4,257 | 10.87 | 62 | 3.39 (3.29-3.5) | 3.70 (3.59-3.81) | 0.94 |
| 3.9 Hairy cell leukemia | 9940 | 274 | 0.70 | 61 | 0.22 (0.19-0.24) | 0.24 (0.21-0.26) | 3.35 |
| 3.10 Plasma cell neoplasms | 9731-9734 | 7,444 | 19.01 | 73 | 5.94 (5.8-6.07) | 6.75 (6.59-6.9) | 1.06 |
| 3.10.1 Solitary plasmocytoma of bone | 9731 | 266 | 0.68 | 66 | 0.21 (0.19-0.24) | 0.24 (0.21-0.27) | 1.56 |
| 3.10.2 Extraosseus plasmocytoma | 9734 | 117 | 0.30 | 68 | 0.09 (0.08-0.11) | 0.10 (0.08-0.12) | 1.85 |
| 3.10.3 Plasma cell myeloma/leukemia | 9732-9733 | 7,061 | 18.03 | 73 | 5.63 (5.5-5.76) | 6.41 (6.25-6.56) | 1.04 |
| 3.11 B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical HL | 9596 | 16 | 0.04 | 46 | 0.01 (0.01-0.02) | 0.01 (0.01-0.02) | 1.00 |
| 4) Mature-T-cell and NK-cell neoplasms | 2,345 | 5.99 | 62 | 1.87 (1.79-1.95) | 2.01 (1.93-2.09) | 1.52 | |
| 4.1 Mycosis fungoides/Sezary syndrome | 9700, 9701 | 840 | 2.15 | 62 | 0.67 (0.62-0.72) | 0.72 (0.67-0.77) | 1.51 |
| 4.2 Peripheral T/NK-cell lymphoma | 9702, 9705, 9708-9709, 9714-9717, 9724-9726 | 1,142 | 2.92 | 63 | 0.91 (0.86-0.96) | 0.98 (0.92-1.03) | 1.63 |
| 4.2.1 Peripheral T-cell lymphoma, NOS | 9702 | 492 | 1.26 | 66 | 0.39 (0.36-0.43) | 0.42 (0.39-0.46) | 1.83 |
| 4.2.2 Angioimmunoblastic T-cell lymphoma | 9705 | 177 | 0.45 | 69 | 0.14 (0.12-0.16) | 0.16 (0.13-0.18) | 1.72 |
| 4.2.3 Subcutaneous panniculitis-like T-cell lymphoma | 9708 | 11 | 0.03 | 69 | 0.01 (0-0.01) | 0.01 (0-0.01) | 1.20 |
| 4.2.4 Anaplastic large cell lymphoma, ALK-positive | 9714 | 195 | 0.50 | 51 | 0.16 (0.13-0.18) | 0.16 (0.14-0.18) | 1.91 |
| 4.2.5 Hepatosplenic T-cell lymphoma | 9716 | 11 | 0.03 | 46 | 0.01 (0-0.01) | 0.01 (0-0.01) | 1.20 |
| 4.2.6 Enteropathy-associated T-cell lymphoma | 9717 | 39 | 0.10 | 56 | 0.03 (0.02-0.04) | 0.03 (0.02-0.04) | 1.79 |
| 4.2.7 Primary cutaneous gamma-delta T-cell lymphoma | 9726 | 0 | 0.00 | NA | 0.00 (0–0) | 0.00 (0–0) | NA |
| 4.2.8 Primary cutaneous T-cell lymphoma, NOS | 9709 | 217 | 0.55 | 61 | 0.17 (0.15-0.2) | 0.19 (0.16-0.21) | 1.09 |
| 4.2.9 Systemic EBV-positive T-cell lymphoproliferative disease of childhood | 9724 | 0 | 0.00 | NA | 0.00 (0–0) | 0.00 (0–0) | NA |
| 4.2.10 Hydroa vacciniforme-like lymphoma | 9725 | 0 | 0.00 | NA | 0.00 (0–0) | 0.00 (00) | NA |
| 4.3 Adult T-cell leukemia/lymphoma | 9827 | 15 | 0.04 | 76 | 0.01 (0.01-0.02) | 0.01 (0.01-0.02) | 0.88 |
| 4.4 Extranodal NK/Tcell lymphoma, nasal type | 9719 | 80 | 0.20 | 60 | 0.06 (0.05-0.08) | 0.07 (0.05-0.08) | 2.08 |
| 4.5 T-cell large granular lymphocytic leukemia | 9831 | 61 | 0.16 | 73 | 0.05 (0.04-0.06) | 0.05 (0.04-0.07) | 1.35 |
| 4.6 T-cell prolymphocytic leukemia | 9834 | 33 | 0.08 | 64 | 0.03 (0.02-0.04) | 0.03 (0.02-0.04) | 0.94 |
| 4.7 Aggressive NK cell leukemia | 9948 | 9 | 0.02 | 67 | 0.01 (0-0.01) | 0.01 (0-0.01) | 0.80 |
| 4.8 Primary cutaneous CD30 + T-cell lymphoproliferative disorders | 9718 | 165 | 0.42 | 56 | 0.13 (0.11-0.15) | 0.14 (0.12-0.16) | 1.09 |
| 5) Lymphoid neoplasms, NOS | 9590, 9591, 9820, 9832, 9970, 9971, 9760, 9762 | 2,141 | 5.47 | 75 | 1.71 (1.64-1.78) | 1.90 (1.82-1.98) | 0.99 |
Bold values highlight the main subtypes and its data.